GLA
BIO icon

Great Lakes Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Great Lakes Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-12,768
Closed -$2.54M – 565
2017
Q1 		$2.54M Sell
12,768
-17,238
-57% -$3.32M 0.07% 232
2016
Q4 		$5.47M Sell
30,006
-11,383
-28% -$1.94M 0.14% 120
2016
Q3 		$6.78M Sell
41,389
-16,157
-28% -$2.45M 0.18% 86
2016
Q2 		$8.23M Buy
57,546
+366
+0.6% +$52.2K 0.22% 74
2016
Q1 		$7.82M Buy
57,180
+18,808
+49% +$2.47M 0.21% 83
2015
Q4 		$5.32M Sell
38,372
-2,531
-6% -$351K 0.16% 112
2015
Q3 		$5.49M Sell
40,903
-445
-1% -$64K 0.17% 93
2015
Q2 		$6.23M Sell
41,348
-39,453
-49% -$5.64M 0.19% 90
2015
Q1 		$10.9M Buy
80,801
+11,326
+16% +$1.4M 0.33% 63
2014
Q4 		$8.38M Buy
69,475
+14,201
+26% +$1.63M 0.26% 73
2014
Q3 		$6.27M Buy
55,274
+31,463
+132% +$3.73M 0.21% 77
2014
Q2 		$2.85M Buy
23,811
+8,866
+59% +$1.08M 0.12% 94
2014
Q1 		$1.92M Buy
14,945
+13,295
+806% +$1.7M 0.08% 136
2013
Q4 		$204K Buy
+1,650
New +$201K 0.01% 320

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Great Lakes Advisors's BIO Position: Q2 2017 in Review

Great Lakes Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2017, closing a stake of 12,768 shares — an estimated $2.54M sold.

Great Lakes Advisors first reported a position in BIO in Q4 2013 and held it in 14 quarters. The position peaked at $10.9M in Q1 2015. 276 funds tracked by Wall St. Rank hold BIO as of Q2 2017.

  • Great Lakes Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2017 after selling out during the quarter.
  • Great Lakes Advisors sold 12,768 Bio-Rad Laboratories Class A shares in Q2 2017, an estimated $2.54M.
  • Great Lakes Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2013 and held it in 14 quarters.
  • Great Lakes Advisors's Bio-Rad Laboratories Class A position peaked at $10.9M in Q1 2015.
  • 276 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2017.

Based on Great Lakes Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.